AI assistant
Roivant Sciences Ltd. — Director's Dealing 2025
Dec 20, 2025
30587_dirs_2025-12-19_408a2cc0-635c-42e8-8c8e-434af1d9689d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2025-12-17
Reporting Person: Sukhatme Mayukh (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | Common Shares | M | 59513 | $12.68 | Acquired | 18896060 | Direct |
| 2025-12-17 | Common Shares | S | 26831 | $23.09 | Disposed | 18869229 | Direct |
| 2025-12-17 | Common Shares | J | 32682 | $23.09 | Disposed | 18836547 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-17 | Common Shares | $12.68 | M | 59513 | Disposed | 2026-03-31 | Common Shares (59513) | Direct |
Footnotes
F1: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
F3: Award of stock options to purchase Common Shares that is fully vested.